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Abstract
Objective—We previously examined the expression of specific C-terminal μ-opioid receptor
(MOR) splice variants in human central nervous system cell types and HIV-infected brain tissue
from subjects with neurocognitive impairment ± HIV encephalitis (HIVE). In the present study,
we examined the N-terminal splice variant MOR-1K which mediates excitatory cellular signaling.
Methods and Results—We found segregation of expression ranging from undetectable to
seemingly exclusive across nervous system cell types compared to the pool of C-terminal MOR
splice variants using RT-PCR. Expression of MOR-1K mRNA was also increased in HIV-infected
subjects with combined neurocognitive impairment and HIVE compared to the other groups.
MOR-1K expression correlated with the level of subject neurocognitive impairment whereas the
pool of C-terminal MOR splice variants did not. HIVE was also associated with increased
expression of the inflammatory mediators MCP-1, MCP-2, and RANTES, but not the host HIV
co-receptors CXCR4 and CCR5 or the CD4 receptor, using qRT-PCR. Network analysis of
microarray data from these same subjects revealed filamin A (FLNA) as a possible interaction
partner with MOR-1K, and FLNA gene expression was also found to be upregulated in HIVE
using qRT-PCR. Overexpression of filamin A in HEK293 cells redistributed MOR-1K from
intracellular compartments to the cell surface.
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Conclusion—These results suggest that HIVE, and neurocognitive impairment depending on its
severity, are associated with enhanced MOR-1K signaling through both increased expression and
trafficking to the cell surface, which may alter the contribution of MOR receptor isoforms and
exacerbate the effects of MOR activation in neuroAIDS.
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Introduction
The μ-opioid receptor (MOR) is comprised of numerous alternatively spliced variants rather
than a single protein entity, and most of the variation has been found to occur in the C-
terminus of the receptor (for a review see [1]). One recently discovered, novel MOR splice
variant termed MOR-1K is preferentially found in the brain, expressed intracellularly, and
differs functionally from the C-terminal canonical MOR-1 variant [2, 3]. Unlike other MOR
splice variants, which encode seven-transmembrane (7TM) spanning domains, the six-
transmembrane (6TM) MOR-1K variant couples to Gαs and stimulates increases in both
intracellular Ca2+ and nitric oxide (NO) release [2, 3]. Accordingly, MOR-1K may uniquely
activate neuroinflammation associated with opioid-dependent hyperalgesia, tolerance, and
dependence [3].
Previous studies have suggested a role for MOR in HIV replication and progression of the
HIV disease leading to neurocognitive impairment, particularly in the context of opioid co-
exposure [4–12]. However, most studies have focused on the canonical MOR-1 without
examining the roles of other MOR splice variants (for a review see [13]). Our previous
association of particular C-terminal MOR splice variants with different stages of the HIV
disease process suggests a dynamic interplay between signaling pathways invoked by HIV
exposure and those regulating opioid receptor levels and processing [14]. To further
investigate the role of MOR variation in relation to neuroAIDS, we examined the
distribution of MOR-1K among human neural cell types and asked whether MOR-1K might
also play a role in HIV neuropathogenesis. By virtue of the excitatory cellular effects
attributed to this variant, we questioned whether MOR-1K might underlie key aspects of
opiate-dependent exacerbation of HIV neuropathogenesis [14–17]. Exaggerated MOR-1K
function has been linked to aberrant opiate actions [2, 3], and may contribute to accelerated
neuropathology seen with chronic opiate abuse in uninfected [18, 19] and HIV-infected
individuals [17, 20]. Therefore, the purpose of this study was to identify the cells in which
MOR-1K is expressed among selected neural cell types and determine whether the
expression of MOR-1K is altered in HIV-infected subjects with varying levels of
neurocognitive impairment which may point to a potential cell-type specific role for this
unique variant in the pathogenesis of neuroAIDS.
Methods
Cells and tissue
Astrocytes, microglia, and neurons were described and characterized previously [14]. Brain
vascular pericytes (catalog number 1200) were purchased from ScienCell Research
Laboratories (Carlsbad, CA, USA) and cultured according to the manufacturer’s
instructions. Total RNA from primary human brain microvascular endothelial (catalog
number 1005) and perineurial (catalog number 1715) cells was also purchased from
ScienCell. Human brain tissue was obtained from the National NeuroAIDS Tissue
Consortium (NNTC) Gene Array Project (http://www.nntc.org/gene-array-project) [21, 22].
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The samples used in this study taken from frontal lobe white matter, frontal cortex, and basal
ganglia of uninfected and HIV-infected subjects ± neurocognitive impairment with and
without HIV encephalitis (HIVE) have been described in detail previously [14].
RT-PCR
RT-PCR was performed essentially as described previously [14]. For detailed methods, see
Supplemental Digital Content 1.
Immunocytochemistry
Brain vascular pericytes in culture were fixed using 4 % paraformaldehyde, permeabilized
with 0.5 % Triton X-100, immunolabeled, and nuclei were stained with DAPI. Primary
antibody to actin alpha 2 smooth muscle (Novus Biologicals, LLC; Littleton, CO, USA;
catalog number NBP1-97722) was used at a 1:25 dilution and visualized with Alexa Fluor
594 conjugated secondary antibody (Molecular Probes; Eugene, OR, USA; catalog number
A-11032) used at a 1:500 dilution. Samples were imaged with a Zeiss LSM 700 laser
scanning confocal microscope at 63× magnification. Images were collected using ZEN 2009
Light Edition software (Carl Zeiss, Inc.; Thornwood, NY, USA) and edited with Adobe
Photoshop CS3 Extended 10.0 software (Adobe Systems, Inc.; San Jose, CA, USA).
HEK293 cells (ATCC; Manassas, VA, USA) were transfected with plasmids encoding
FLAG-tagged MOR-1K [3] and/or Myc-tagged filamin A (pcDNA3-Myc-FLNA WT,
Addgene plasmid 8982 [23]) using Lipofectamine 2000 reagent (Invitrogen; Carlsbad, CA,
USA). Forty-eight hours post-transfection, cells were fixed in −20°C methanol,
permeabilized with 0.25 % Triton X-100, immunolabeled, and nuclei were stained with
Hoechst 33342. Primary antibodies were anti-FLAG and anti-Myc epitope tag (Cell
Signaling Technology, Inc.; Danvers, MA, USA) used at a 1:200 dilution and anti-Filamin 1
(Santa Cruz Biotechnology, Inc.; Dallas, TX, USA; catalog number sc-17749) used at a
1:100 dilution. Primary antibodies were visualized with appropriate secondary antibodies
conjugated to Alexa Fluor 488 or 594 (Molecular Probes; Eugene, OR, USA). Samples were
imaged using a Zeiss LSM 710 confocal microscope and images were collected and
analyzed with ZEN software.
Microarray data analysis
CEL files for arrays were retrieved from the NCBI Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/), GEO accession number GSE35864 [21]. Probe intensity data
from chips hybridized with samples from each brain region was normalized and summarized
separately using robust multi-array average (RMA) analysis [24]. Probesets that were
consistently absent (based on MAS 5.0 detection calls) across all arrays within a brain
region were excluded from the subsequent analysis of that subset of arrays. Differential
expression between subject groups was assessed using multi-class linear models for
microarray data (Limma) analysis [25], and Limma output p-values were adjusted by
Benjamini and Hochberg’s false discovery rate correction for multiple testing [26], setting
the significance level to 0.05. Overlap in genes that were significantly different between the
HIV-negative versus HIVE groups in the frontal lobe white matter, frontal cortex, and basal
ganglia was assessed using Gene Weaver (http://geneweaver.org/) [27]. Additional
bioinformatics analysis was performed using the ToppNet function of ToppGene Suite
(http://toppgene.cchmc.org/) [28]. OPRM1 was used as the training set and overlapping
genes from the above analysis were used as the test set with a K-step Markov prioritization
method, step size 6 and neighborhood distance of 1.
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All statistical analyses were performed using GraphPad Prism 5 software (GraphPad
Software, Inc.; La Jolla, CA, USA). qRT-PCR data was analyzed by either one-way
ANOVA and Bartlett’s test for equal variances followed by Student Neuman-Keuls post-hoc
test for multiple comparisons or Student’s unpaired, two-tailed t test for paired data. A value
of p < 0.05 was considered significant.
Results
MOR-1K is differentially expressed across nervous system cell types
We examined the expression profile of MOR-1K compared to the pool of C-terminal MOR
splice variants (denoted MOR-1(exons 1–2)) in various nervous system cell types by RT-PCR
using primer sets targeting specific exons (Fig. 1a). As the protein sequence differs from the
canonical MOR-1 only in that the first 100 amino acids of the N-terminal first
transmembrane domain are deleted (Fig. 1b), it is not possible to design an antibody that will
specifically recognize MOR-1K. Expression profiling of MOR-1K in astrocytes, microglia,
and neurons revealed detection in astrocytes, but not microglia and neurons, while
MOR-1(exons 1–2) was detected in all three cell types (Fig. 1c). The expression level of
MOR-1K in astrocytes was much lower compared to MOR-1(exons 1–2) (Fig. 1d).
We additionally examined MOR expression in brain microvascular endothelial cells and
brain vascular pericytes, as well as perineurial cells from the peripheral nervous system
which provide a selective barrier function likened to the blood-brain barrier within larger
peripheral nerves [29– 31]. These three cell types were assessed based on reports that opiate
drugs alone or in the context of HIV infection can directly affect blood-brain barrier
permeability [32, 33], and to begin to explore the role of MOR-1K in known differences
with the central versus peripheral actions of opiate analgesics on the nervous system [30,
31]. Interestingly, when we examined brain microvascular endothelial and perineurial cells
for MOR expression, we were only able to detect MOR-1K but not MOR-1(exons 1–2) (Fig.
1e), suggesting exclusive expression of this particular MOR variant in these cell types.
However, the detection level of MOR-1K was lower in these two cell types than in
astrocytes suggesting a lower overall level of expression (Fig. 1f). We were unable to detect
MOR-1(exons 1–2) and MOR-1K expression in cultured brain vascular pericytes (Fig. 1g,h).
These results suggest that MOR-1K is differentially expressed across nervous system cell
types, similar to previous findings of C-terminal MOR variant segregation across cell types
from the central nervous system [14].
MOR-1K expression is increased in human subjects with HIVE
As increases in MOR expression may be a contributing factor to HIV disease pathology [14,
34–36], we next examined whether the expression level of MOR-1K differed across HIV-
infected subjects with varying levels of neurocognitive impairment using qRT-PCR. While
MOR-1(exons 1–2) did not show any overall significant differences, MOR1-K showed
differences between HIVE subjects and the other HIV-infected groups, as well as uninfected
subjects when untransformed data was analyzed (Fig. 2a,b). However, the analysis revealed
that the group variances were non-homogeneous (p < 0.05; Bartlett’s test), which was
anticipated considering the relative low abundance of MOR-1K transcripts, as well as
challenges in obtaining consistent human samples from the same brain region, differing
postmortem intervals, and RNA quality. Accordingly, the data was log transformed. We also
found a non-significant trend of progressively decreasing expression with HIV-infected and
HIV-infected/impaired subjects compared those that were uninfected for both
MOR-1(exons 1–2) and MOR-1K. In addition, when the level of neurocognitive impairment
for each HIV-infected subject with deficiencies and those with HIVE was compared to
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MOR expression levels, MOR-1K showed a significant correlation whereas
MOR-1(exons 1–2) did not (Fig. 2c). These results suggest that the MOR-1K variant is
specifically upregulated in HIVE and that the level of its expression is associated with the
severity of neurocognitive deficits found in HIV patients.
HIVE is associated with increases in mRNAs for inflammatory chemokines but not host
HIV entry factors
To confirm that the HIVE subjects we examined had increases in inflammation, we
examined the expression levels of MCP-1, MCP-2, and RANTES using qRT-PCR. All three
inflammatory mediators were significantly increased between HIVE and all the other groups
of subjects examined (Fig. 3a – c). We also examined the mRNA expression levels of the
HIV co-receptors CXCR4 and CCR5, as well as the CD4 receptor, since host proteins that
interact with HIV have been shown to form functional complexes with opioid receptors,
including MOR, to affect cellular signaling and possibly processes such as viral entry [37–
43]. We did not detect any overall significant differences for these co-receptors and receptor,
although there was a trend of increased CXCR4 expression across the groups of HIV-
infected compared to uninfected subjects (Fig. 3d – f).
Filamin A is an interaction target for MOR-1K in HIVE
During the course of this study, microarray data was recently published on the same subjects
that we examined [21]. The deposited data files were retrieved for reanalysis to determine
the most likely candidate to interact with MOR in the context of HIV infection. Our analysis
confirmed the previous finding that most of the differences in gene expression occurred
between the uninfected and HIVE subjects [21], versus the other group pair-wise
comparisons (see Figure, Supplemental Digital Content 2). For the three brain regions that
were examined from uninfected and HIVE subjects, we found a total of 116 genes that
overlapped between different sets of brain regions which were significantly different
between these two groups (Fig. 4a). Most of the overlapping genes (114) occurred between
the frontal cortex and basal ganglia which also included the genes (7) overlapped between
the frontal lobe white matter and frontal cortex, with an additional two genes (GPNMB and
ISG15) overlapped between the frontal lobe white matter and basal ganglia that did not
occur between other regions. We then performed a proteinprotein interaction network
analysis to determine which of the protein products from these 116 genes might interact with
the products of the OPRM1 gene in HIVE. This analysis scored and ranked the 116
overlapping candidate genes based on topological features of global networkdistance
measures on the relative location to OPRM1 (MOR) in a protein-protein interaction network
generated using existing datasets from assays such as high-throughput yeast two-hybrid
screens [28, 44, 45]. The resulting network revealed the product of the FLNA gene, filamin
A, as a likely protein-protein interaction partner with MOR (Fig. 4b; Table 1). We then
confirmed that FLNA mRNA was expressed in the cell types that we identified as also
expressing MOR-1K mRNA (Fig. 4c), suggesting the possibility that filamin A could
interact with MOR-1K in these cell types in vivo. Additionally, we found that FLNA
expression levels were increased between uninfected and HIVE subjects using qRT-PCR
(Fig. 4d).
Filamin A has previously been shown to interact with the C-terminus of the canonical
MOR-1 [46, 47]. As MOR-1K has the same C-terminal sequence, it was therefore possible
that this MOR variant would also form interactions with filamin A. When the overexpressed
alone condition was assessed in HEK293 cells, MOR-1K localized mainly within
intracellular compartments as previously reported [3], whereas filamin A showed peripheral
cytoplasmic localization (Fig. 4e). However, when both proteins were overexpressed, we
found that not only did filamin A co-localize with MOR-1K, but that this co-localization
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occurred at the cell surface (Fig. 4f). Although HEK cells endogenously express filamin A
[46], basal levels were not sufficient to carry MOR-1K to the cell surface and required
filamin A overexpression.
Discussion
In this study, we sought to determine the role of the N-terminal truncated MOR splice
variant MOR-1K in HIV pathogenesis. We first examined the expression profile of
MOR-1K in cell types from the nervous system and detected expression in astrocytes, brain
microvascular endothelial and perineurial cells, but not in microglia, neurons, or brain
vascular pericytes. We previously examined the expression profiles of the C-terminal MOR
splice variants MOR-1A and MOR-1X, as well as MOR-1, across astrocytes, microglia, and
neurons and also observed heterogeneity in expression [14]. All three variants were
expressed in astrocytes, but MOR-1A was the only variant also detected in microglia and
neurons. Combined with the findings of the present study, these results suggest that vastly
different functions of MOR may be conferred on individual cell types by virtue of their
balance of splice variants. Since astrocytes appear to be the cell type in the brain harboring
most of the MOR splice variants, astroglia are thus likely to have a major contribution to the
effects of morphine on interactions with HIV [16, 48–52].
In addition, our findings regarding the seemingly exclusive expression of MOR-1K in brain
microvascular endothelial and perineurial cells, but lack of MOR in brain vascular pericytes,
have important implications for the mechanisms of HIV-opioid interactions at the blood-
brain barrier. Interestingly, it was shown that astrocytes co-cultured with brain
microvascular endothelial cells had elevated calcium responses to opioid agonists compared
to astrocytes cultured alone [53]. This finding suggests that the brain microvascular
endothelial cells, through responses mediated by MOR-1K, could alter astroglial signaling
and enhance inflammatory tone in these cells. Although placental pericytes have been shown
to respond to morphine treatment [54], our inability to detect any MOR expression in the
brain derivative suggests the possibly that other receptors such as TLR4 are contributing to
the effects of opioids in this cell type [55, 56]. Additionally, while pericytes from human
brain have recently been shown to productively infect with HIV at low levels [57], it is
generally believed that although HIV can enter brain microvascular endothelial cells,
productive infection does not occur in this cell type [58, 59]. Thus, if the brain
microvascular endothelial cells are enhancing excitatory responses to morphine that affect
astroglia, and pericytes are mediating the consequences of productive HIV infection,
differential contributions from HIV and/or morphine exposure by each cell type may result
in altered cellular cross-talk that could disrupt the integrity of the blood-brain barrier beyond
the effects of HIV or morphine alone. Future studies will be needed to further elucidate the
responses of these cell types derived from the central nervous system to HIV and morphine,
and the interactive signaling pathways invoked by each that could synergistically disrupt the
blood-brain barrier.
Our findings also suggest that increases in MOR-1K mRNA expression levels during HIVE
occur simultaneously with increases of mRNAs from known inflammatory mediators. HIVE
tissues had the highest MOR-1K levels, significantly higher than samples from cognitively
impaired subjects without encephalitis. At first glance, the results suggest that MOR-1K
transcript levels are differentially increased by encephalitis, irrespective of neurocognitive
impairment. However, when MOR-1K mRNA expression levels were correlated with the
degree of cognitive impairment, heightened MOR-1K levels were highly related to severity
of the deficits (Fig. 2c). While these results appear to be disparate, they might be reconciled
if we could examine a subset of HIVE patients without cognitive impairment, or if more
details concerning characteristics of the HIVE and cognitively impaired groups were
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available. A pattern of pronounced differences in gene expression from neurocognitively-
impaired HIVE(+) versus HIVE(−) individuals in these sample pools have prompted the
notion that there are “two types of HIV-associated neurocognitive impairment” [21].
Interestingly, MOR-1(exons1–2) transcript levels were unaffected by HIV, HIVE, or the
degree of cognitive impairment, implying fundamental differences in the response of C-
terminal MOR splice variants compared to MOR-1K in neuroAIDS. Although assumed to
result from encephalitis, we cannot exclude the possibility that increasing levels of MOR-1K
contribute to HIVE and cognitive deficits. The onset of neurocognitive impairment may be
independent of inflammation, although, if HIVE develops, it could clearly worsen a decline
in cognition. It should be noted that for the 116 overlapping genes from the three brain
regions examined that had significant differences between uninfected and HIVE subjects,
our analysis found that CCL5/RANTES ranked fourth in protein-protein interactions with
MOR (Table 1).
Opioid receptors, including MOR, have also been shown to form functional complexes with
both CXCR4 and CCR5, possibly in combination with CD4, to affect cellular signaling and
potentially viral entry by bidirectional heterologous interactions [37–43]. However, we did
not find any overall significant differences in CXCR4, CCR5, or CD4 mRNA expression
levels across the groups of HIV-infected subjects. This result suggests that MOR-1K mRNA
expression levels are quite sensitive to changes in the brain that occur with HIVE, perhaps
more sensitive than the major HIV co-receptors and receptor, and that MOR may be
particularly important in mediating cellular signing and viral entry processes related to
CXCR4 and CCR5 [60]. For example, the CCR5Δ32 mutant has been shown to be retained
in the endoplasmic reticulum, similarly to MOR-1K, and to scavenge both wild-type CCR5
and CXCR4 [61]. If MOR-1K acts similarly and forms intracellular complexes with CXCR4
and CCR5, this could be another mechanism by which MOR-1K modulates HIV co-receptor
signaling. Interestingly, we did not find that overexpression of either CXCR4 or CCR5 with
MOR-1K resulted in the translocation of MOR-1K to the cell surface (data not shown),
suggesting that such complexes would be retained intracellularly. Future studies will be
needed to determine the specific MOR splice variants that form heterodimers with the HIV
co-receptors and the differential effects of heterodimers containing individual MOR variants
on cellular signaling and viral entry.
For MOR-1K to affect viral entry it would need to be expressed on the cell surface. Our
network analysis of the genes that were significantly regulated across the three brain regions
examined between uninfected and HIVE subjects showed that filamin A was the most likely
candidate to interact with MOR. Filamin A has previously been shown to interact with the
C-terminal tail of the canonical MOR-1 and affect receptor trafficking [46, 47]. We
therefore speculated that filamin A would also interact with the same C-terminal sequence of
MOR-1K and possibly affect trafficking of this MOR variant. Accordingly, we found that
overexpression of filamin A trafficked MOR-1K to the surface of transfected HEK293 cells.
These results are important for patients with the HIVE condition as we also found that
FLNA expression levels were increased in HIVE subjects, suggesting that MOR-1K may be
more highly expressed on the surface of cells during this condition. We confirmed that
FLNA mRNA was expressed in all the cell types we examined that also expressed MOR-1K
mRNA. Future studies will be needed to determine the effects of HIV exposure on FLNA
expression levels in these individual cell types. However, as the differences we detected
were in the HIVE subject group, the chronic effects of in vivo HIV infection may be difficult
to model using current isolated and co-cultured cell culture systems, and particularly in
murine cell systems and in vivo models [62].
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In conclusion, our results highlight the potential role of a unique MOR splice variant in the
central nervous system effects of HIV, particularly in the context of HIVE. From this and
our previous study, we speculate that out of the MOR-1, MOR-1A, MOR-1X, and MOR-1K
variants, MOR-1K is most likely to play a major role in HIV disease pathology. However, as
HIV-infected individuals with the A118G (N40D) polymorphism located in exon 1 of the
receptor have more severe disease progression [63], certain C-terminal MOR variants must
also play a role. Characterization of the particular MOR splice variants involved and their
molecular interactions could lead to unique strategies for tailored drug design directed
towards targeting specific MOR variants. Moreover, while the consequences of MOR-1K
expression at the plasma membrane have yet to be determined in terms of altered cellular
signaling properties, many other interesting possibilities exist such as the formation of
complexes with CXCR4 and CCR5 that could directly affect non-canonical processes
involving MOR such as viral entry.
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Fig. 1. MOR-1K expression in various human nervous system cell types
(a) Schematic representation of the 4 exons (E) comprising the MOR-1 and MOR-1K
mRNA products of the OPRM1 gene. Arrows denote the locations of PCR primers used in
which a common reverse primer targeted exon 2 and the forward primers targeted either
exon 1 of MOR-1 or the MOR-1K specific exon 13. (b) Schematic representation of the
MOR-1 and MOR-1K (100 amino acids (aa) deleted) proteins with the C-terminal sequence
within exon 4 shown. (c) MOR-1 (denoted MOR-1(exons 1–2)) and MOR-1K PCR products
amplified from the indicated cell types. PCR products were detected using 2 % agarose gels
stained with ethidium bromide. Marker indicates 100 base pair (bp) DNA ladder marker
where the 100 and 200 bp markers are shown. GAPDH served as a loading control. (d)
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Quantification of results from astrocytes in c. Error bars show the SEM. (e) PCR products
amplified from brain microvascular endothelial cells (BMEC) and peripheral nervous
system perineurial cells (PNC). (f) Quantification of results for MOR-1K from the cell types
in e compared to astrocytes. (g) PCR products amplified from brain vascular pericytes
(BVP). The human neuroblastoma cell line SHSY-5Y (which is heavily enriched in MORs)
served as a positive control. (h) Characterization of pericytes from g by
immunocytochemistry using actin alpha 2 smooth muscle as a cell type marker and DAPI to
label cell nuclei. A differential interference contrast microscopy image is also shown. All
experiments and error bars are representative of at least 3 individual lots of primary cells
from different individuals.
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Fig. 2. Expression of MOR-1K across HIV-infected subjects with varying levels of
neurocognitive impairment
Expression levels of (a) MOR-1(exons 1–2) and (b) MOR-1K were measured by qRT-PCR
across the indicated groups of subjects. Error bars show the SEM. F(3,24) = 2.965, p =
0.0522 for MOR-1(exons 1–2) and F(3,23) = 4.600, p = 0.0116 (untransformed data); F(3,23)
= 4.137, p = 0.0175 (log transformed data) for MOR-1K. *p < 0.05 vs. all other groups
(untransformed data); *p < 0.05 vs. other HIV-infected groups (log transformed data). (c)
Linear regression line modeling the correlation between expression levels of
MOR-1(exons 1–2) and MOR-1K with Global Impairment Scores for individual subjects in
the HIV-infected and HIVE groups with neurocognitive impairment. Pearson correlation
coefficient (r) = 0.2238, p = 0.4844 for MOR-1(exons 1–2) and r = 0.5992, p = 0.0395 for
MOR-1K. For the impairment score and neurocognitive diagnosis, a description of each
subject included in the NNTC Gene Array Project is summarized (see Table, Supplemental
Digital Content 3).
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Fig. 3. Expression of mRNAs for inflammatory mediators and host HIV entry proteins in HIV-
infected subjects
Expression levels of the inflammatory mediators (a) CCL2/MCP-1, (b) CCL8/MCP-2, and
(c) CCL5/RANTES and the host HIV entry proteins (d) CXCR4, (e) CCR5, and (f) CD4
were measured by qRT-PCR across the indicated groups of subjects. Error bars show the
SEM. F(3,24) = 4.067, p = 0.0181 for CCL2/MCP-1; F(3,24) = 8.872, p = 0.0004 for CCL8/
MCP-2; F(3,24) = 4.186, p = 0.0162 for CCL5/RANTES; F(3,24) = 1.889, p = 0.1585 for
CXCR4; F(3,24) = 0.7240, p = 0.5476 for CCR5; and F(3,24) = 0.1067, p = 0.9553 for
CD4. *p < 0.05 vs. all other groups.
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Fig. 4. Filamin A expression in HIVE and alterations to MOR-1K subcellular trafficking
(a) Venn diagram of significantly regulated overlapping genes between the indicated brain
regions from uninfected and HIVE subjects examined in a microarray study. (b) Network
analysis of protein-protein interactions between the products of the 116 overlapping genes
from a with the products of the OPRM1 gene. (c) FLNA PCR products amplified from
astrocytes, brain microvascular endothelial cells (BMEC), and perineurial cells (PNC). PCR
products were detected using 2 % agarose gels stained with ethidium bromide. Marker
indicates 100 base pair (bp) DNA ladder marker where the 100, 200, and 300 bp markers are
shown. GAPDH served as a loading control. Bands are representative of 3 individual lots of
primary cells from different individuals. (d) Expression levels of the filamin A gene, FLNA,
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were measured by qRT-PCR for the indicated groups of subjects. Error bars show the SEM.
p = 0.0075. *p < 0.05 vs. uninfected group. (e) Representative images of HEK293 cells
transiently transfected with plasmids encoding either epitope FLAG-tagged MOR-1K or
Myc-tagged filamin A and immunolabeled with either anti-FLAG (green) or anti-Myc (red)
antibodies. (f) HEK293 cells co-transfected with plasmids encoding filamin A and MOR-1K
co-immunolabeled with anti-filamin A (red) and anti-FLAG (green) antibodies. Cells were
counterstained for nuclear DNA (blue). Arrow denotes MOR-1K localization at the plasma
membrane. Scale bars = 10 µm.
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